{"entity":{"id":"nct06805305","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","aka":[],"tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Diakonos Oncology Corporation, now recruiting.","summary":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) is a phase 2 interventional study registered as NCT06805305 by Diakonos Oncology Corporation, with 180 participants planned, started 2025-03-17 and due to reach its primary completion in 2030-03. Interventions recorded: DOC1021, Tumor resection, Temodar (Temozolomide) and SOC cranial radiation.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06805305","url":"https://clinicaltrials.gov/study/NCT06805305"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":["diakonos-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06805305","phase":"2","setting":"Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma","sponsor":"Diakonos Oncology Corporation","enrolled":180,"outcomes":[]},"route":"/trials/nct06805305/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"doc1021","kind":"drug","name":"DOC1021","route":"/drugs/doc1021/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/"}]}}